New combo therapy targets tough lymphoma

NCT ID NCT05873712

First seen Jan 05, 2026 · Last updated May 17, 2026 · Updated 20 times

Summary

This study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that has returned or not responded to prior treatment. About 24 participants will receive both treatments to see if the combination can shrink or eliminate cancer. The goal is to improve response rates while monitoring safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.